Advertisement

Partial destruction of noradrenergic terminals is followed by increased tyrosine hydroxylase activity in residual terminals

  • M J Zigmond
  • A L Acheson
  • E M Stricker

Abstract

Intraventricular administration of 6-hydroxydopamine produced a relatively small decline in tyrosine hydroxylase (TH) activity in rat hippocampus despite the widespread degeneration of central noradrenergic nerve terminals. This increase in the ratio of TH activity to norepinephrine content appeared to result from two temporally distinct processes. At first, within 36 hours after the lesion, the apparent Vmax of TH decreased in parallel to the loss of norepinephrine but there was a marked increase in the affinity of the enzyme for cofactor, resembling the effects of in vitro phosphorylation. Subsequently, this activation of the enzyme declined but the apparent Vmax of TH gradually increased in a manner suggesting an increase in the amount of TH per residual terminal. These short and long term alterations in TH activity after 6-hydroxydopamine treatment may represent adaptive responses to the lesion.

Keywords

Tyrosine Hydroxylase Locus Coeruleus Lesion Animal Tyrosine Hydroxylation Noradrenergic Terminal 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Acheson, A.L., Kapatos, G. and Zigmond, M.J. (1981) Life Sci., 28. 1407–1420.Google Scholar
  2. Acheson, A.L., Zigmond, M.J. and Stricker, E.M. (1979) Trans. Amer. Soc. Neurochem., 10, 142.Google Scholar
  3. Acheson, A.L., Zigmond, M.J. and Stricker, E.M. (1980) Science, 207, 537–540.Google Scholar
  4. Acheson, A.L. and Zigmond, M.J. (1981) J. Neurosci., in press.Google Scholar
  5. Buda, M., Roussel, B., Renaud, B. and Pujol, J.F. (1975) Brain Res., 93, 564–569Google Scholar
  6. Cannon, W.B., Newton, H.F., Bright, E.M., Menkin, V. and Moore, R.M. (1929) Amer. J. Physiol., 89, 84–107.Google Scholar
  7. Cedarbaum, J.M. and Aghajanian, G.K. (1976) Brain Res., 112, 413–419.Google Scholar
  8. 413.
    Gauthier, P., Nadeau, R.A. and deChamplain (1972) Circ. Res., 31, 207–217.Google Scholar
  9. Hornykiewicz, O. (1973) Biochem. Pharmacol., 24, 1061–1065.Google Scholar
  10. Kapatos, G. and Zigmond, M.J. (1979) J. Pharmacol. Exp. Therap., 208, 468–475.Google Scholar
  11. Lloyd, K.G., Davidson, L. and Hornykiewicz, O. (1975) J. Pharmacol. Exp. Therap., 195, 453–464.Google Scholar
  12. Lloyd, T. and Kaufman, S. (1974) Biochem. Biophys. Res. Commun., 59, 1262–1269.Google Scholar
  13. Morgenroth, V.H., Boadle-Biber, M. and Roth, R.H. (1974) Proc. Natl. Acad. Sci. USA, 71, 4283–4287.Google Scholar
  14. Roth, R.H., Salzman, P.M. and Morgenroth, V.H. (1974) Biochem. Pharmacol., 23, 2779–2784.Google Scholar
  15. Saller, C.F. and Zigmond, M.J. (1978) Life Sciences, 23, 1117–1130.Google Scholar
  16. Stricker, E.M. and Zigmond, M.J. (1976) Progress in Psychobiology and Physiological Psychology Vol. 6, ed. by J.M. Sprague and A.N. Epstein, Academic Press, Inc., New York. pp. 121–188.Google Scholar
  17. Thoenen, H., Mueller, R.A. and Axelrod, J. (1969) J. Pharmacol. Exn. Therap.. 169. 249–254.Google Scholar
  18. Uretsky, N.J. and Iversen, L.L. (1970) J. Neurochem., 17, 269–278.CrossRefPubMedGoogle Scholar
  19. Zigmond, M.J. and Stricker, E.M. (1974) Neuropsychopharmacology of Monoamines and Their Regulatory Enzymes, ed. by E. Usdin, Raven Press, New York, pp.385–402.Google Scholar
  20. Zigmond, R.E. (1979) J. Neurochem., 32, 23–29.CrossRefPubMedGoogle Scholar
  21. Zigmond, R.E., Chalazonitis, A., Joh, T. (1981) Neuroscience Letters, 20, 61–65.Google Scholar

Copyright information

© The Contributors 1981

Authors and Affiliations

  • M J Zigmond
    • 1
  • A L Acheson
    • 1
  • E M Stricker
    • 1
  1. 1.University of PittsburghPittsburghUSA

Personalised recommendations